Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 05 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-3.45 Insider Own67.31% Shs Outstand2.04M Perf Week23.59%
Market Cap23.73M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float0.67M Perf Month-25.51%
Income-21.52M PEG- EPS next Q- Inst Own2.22% Short Float / Ratio4.24% / 1.69 Perf Quarter-38.18%
Sales0.01M P/S2372.52 EPS this Y- Inst Trans- Short Interest0.03M Perf Half Y-64.08%
Book/sh-12.39 P/B- EPS next Y- ROA-79.05% Target Price160.00 Perf Year-64.54%
Cash/sh4.04 P/C2.88 EPS next 5Y- ROE- 52W Range8.47 - 42.00 Perf YTD-56.13%
Dividend- P/FCF- EPS past 5Y31.28% ROI- 52W High-72.31% Beta0.31
Dividend %- Quick Ratio0.99 Sales past 5Y827.99% Gross Margin-900.00% 52W Low37.39% ATR1.67
Employees13 Current Ratio0.99 Sales Q/Q- Oper. Margin-301533.33% RSI (14)41.29 Volatility22.42% 12.54%
OptionableNo Debt/Eq- EPS Q/Q-6074.67% Profit Margin-239077.78% Rel Volume0.72 Prev Close12.08
ShortableYes LT Debt/Eq- EarningsNov 09 AMC Payout- Avg Volume16.75K Price11.63
Recom1.00 SMA20-11.82% SMA50-27.48% SMA200-55.16% Volume12,134 Change-3.73%
Date Action Analyst Rating Change Price Target Change
May-30-19Initiated H.C. Wainwright Buy
Apr-10-18Downgrade Stifel Buy → Hold $12 → $1
Mar-08-18Initiated ROTH Capital Buy $17
Feb-08-18Initiated Northland Capital Outperform $28
Sep-26-16Initiated H.C. Wainwright Buy $13
Sep-04-15Initiated Canaccord Genuity Buy $15
Aug-24-15Initiated Stifel Buy $17
Aug-24-15Initiated Piper Jaffray Overweight $24
Nov-09-23 05:06PM
Nov-08-23 08:00AM
Nov-02-23 08:00AM
Nov-01-23 08:00AM
08:30AM Loading…
Sep-27-23 08:30AM
Sep-26-23 08:30AM
Sep-22-23 05:22AM
Sep-18-23 08:30AM
Aug-24-23 12:35PM
Aug-16-23 02:44PM
Aug-11-23 04:37PM
Aug-10-23 08:33AM
Jun-16-23 08:00AM
07:33AM Loading…
Jun-15-23 07:33AM
May-24-23 09:00AM
May-12-23 08:11AM
May-11-23 04:33PM
Apr-20-23 08:00AM
Mar-30-23 08:31AM
Mar-17-23 01:01PM
Mar-06-23 06:11PM
Mar-03-23 05:06AM
Feb-27-23 08:02AM
Feb-01-23 05:00PM
Jan-20-23 09:03AM
08:00AM Loading…
Jan-09-23 08:00AM
Dec-22-22 06:00AM
Dec-13-22 08:15AM
Dec-03-22 07:04AM
Nov-15-22 02:46PM
Nov-10-22 06:45PM
Nov-02-22 07:26AM
Sep-23-22 07:04AM
Aug-19-22 12:42PM
Aug-18-22 06:41AM
Aug-15-22 06:43PM
Aug-13-22 08:25AM
Aug-09-22 06:09AM
Jul-27-22 03:01PM
Jul-25-22 08:22AM
Jun-04-22 11:00AM
Jun-01-22 06:54AM
May-19-22 06:40AM
May-12-22 07:45AM
Mar-31-22 07:34PM
Mar-29-22 09:47PM
Mar-03-22 08:48PM
Jan-13-22 08:30AM
Jan-12-22 05:38PM
Dec-06-21 06:43PM
Dec-03-21 10:00AM
Nov-22-21 06:06AM
Nov-09-21 09:45AM
Oct-28-21 03:06PM
Oct-20-21 09:00AM
Oct-12-21 07:30AM
Sep-23-21 04:30PM
Sep-13-21 03:40PM
Aug-17-21 10:00AM
Aug-04-21 07:15PM
Jul-27-21 07:50AM
Jun-29-21 07:30AM
Jun-22-21 09:48PM
May-25-21 07:57AM
May-05-21 08:45PM
Apr-14-21 09:03AM
Apr-13-21 07:30AM
Apr-12-21 04:30PM
Mar-23-21 07:30AM
Mar-18-21 04:05PM
Mar-08-21 04:05PM
Mar-03-21 04:21AM
Feb-24-21 04:30PM
Feb-23-21 10:30AM
Feb-17-21 04:05PM
Jan-06-21 04:30PM
Dec-15-20 06:15PM
Dec-02-20 12:50PM
Nov-28-20 08:51PM
Nov-24-20 04:30PM
Nov-05-20 04:30PM
Nov-04-20 07:30AM
vTv Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. Its products target the treatment of central nervous system disorders, diabetes and metabolic disorders, inflammation, and cancer. It offers Azeliragon, TTP399, TTP273, HPP593, HPP737, and the Nrf2/Bach1 program. The company was founded on April 2, 2015 and is headquartered in High Point, NC.